Abstracts tagged "pediatrics"

Abstract Number: 1399 • 2016 ACR/ARHP Annual Meeting
Transitioning Lupus Patients from Pediatric to Adult Rheumatology
Joyce Hui-Yuen¹, Ashlea Cook², Lisa F. Imundo³, Amy Starr², Andrew Eichenfield⁴ and Anca D. Askanase⁵, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ³Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ⁴Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Pediatric rheumatologists have successfully improved the life expectancy and quality of life of children with systemic lupus (cSLE). cSLE has higher morbidity and mortality…
Abstract Number: 2416 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Nikolay Tzaribachev³, Zbigniew Zuber⁴, Elena Koskova⁵, Ivan Foeldvari⁶, Eizbieta Smolewska⁷, Gerd Horneff⁸, Charles Mebus⁹, Umberto Conte¹⁰, Rong Wang⁹, Christine Alvey⁹, Manisha Lamba⁹, Anasuya Hazra¹¹, Daniel Lovell¹² and Alberto Martini¹³, ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁵Institute of Rheumatic Diseases, Piestany, Slovakia, ⁶Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁷Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Collegeville, PA, ¹²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients with rheumatoid arthritis (RA). We report the pharmacokinetics (PK), safety and…
Abstract Number: 2456 • 2015 ACR/ARHP Annual Meeting
Anti SRP+Ve Myositis in Childhood. Presentation and Physiotherapy Treatment of This Rare Childhood Myositis
Susan Maillard and Clarissa Pilkington, Paediatric Rheumatology, Great Ormond Street Hospital NHS Foundation Trust for Children, London, United Kingdom
Background/Purpose: Previously it was understood that all Myositis in childhood was Juvenile Dermatomyositis. More recently Myositis specific antibodies have been discovered and these appear to…
Abstract Number: 2457 • 2015 ACR/ARHP Annual Meeting
Physical Function and Psychological Well-Being in Teens with Juvenile Idiopathic Arthritis (JIA): Characterization and Exploration of Technology-Assisted Self-Management
Carrie Shotwell¹, Paula Melson², Jason Long³ and Tracy Ting⁴, ¹Occupational therapy and physical terapy, Cincinnati Children's Hospital Medical Center, CINCINNATI, OH, ²Rheumatology, Children's Hosp Medical Center, Cincinnati, OH, ³Orthopaedic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology/MLC 4010, Cincinnati Children's Hosp, Cincinnati, OH
Background/Purpose: This study sought to assess the physical function and psychological well- being of teens with juvenile idiopathic arthritis (JIA) as well as to assess…
Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting
Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Gail Deutsch^1,2, Megan Yuasa³ and Anne M. Stevens^4,5, ¹Pathology, Seattle Children's Hospital, Seattle, WA, ²School of Medicine, University of Washington, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ⁵Pediatrics, University of Washington, Seattle, WA
Background/Purpose: The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…
Abstract Number: 3267 • 2015 ACR/ARHP Annual Meeting
Functional Disability in Adolescents Is Predicted By Self-Report of Sleep Problems, Depressive Symptoms, Low Physical Activity and Worst Pain Intensity Levels
Kari Firestone¹, Kim Jones² and Anna Wilson³, ¹School of Nursing, Oregon Health & Science University, Portland, OR, ²Rsch & Develop/Mail Code SN OR, Oregon Health Sciences Univ, Portland, OR, ³OHSU Institute on Development and Disability, Oregon Health & Science University, Portland, OR
Background/Purpose: Pain intensity has been shown to be important in understanding pain related functional disability in adolescents. Additional factors may affect other critical outcomes including…
Abstract Number: 2164 • 2013 ACR/ARHP Annual Meeting
Rituximab In The Treatment Of Children With Systemic LUPUS Erythematosus: ONE Year Analysis Of 12 Patients
Ekaterina Alexeeva^1,2, Rina Denisova², Saniya Valieva², Tatyana Bzarova², Kseniya Isayeva², Tatyana Sleptsova², Elena Mitenko², Evgeniya Chistyakova^1,2, Anna Fetisova² and Elena Semikina³, ¹I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ²Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ³Clinical Laboratory, Scientific Center of Children's Health of RAMS, Moscw, Russia
Background/Purpose: Treatment of childhood systemic lupus erythematosus (SLE) is an ongoing problem because of the severity of the disease in some patients and the side-effects…
Abstract Number: 2596 • 2012 ACR/ARHP Annual Meeting
Rituximab Treatment for Antineutrophil Cytoplasmic Antibody – Associated Vasculitis in Children
Katharine F. Moore¹, Leonard L. Dragone², Jennifer B. Soep³ and J. Roger Hollister⁴, ¹Pediatric Rheumatology, Seattle Children's Hospital / University of Washington, Seattle, WA, ²Dept of Pediatrics, National Jewish Health, Denver, CO, ³Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, ⁴Dept of Pediatrics, Children's Hospital Colorado, Aurora, CO
Background/Purpose: The purpose of this study was to report the experience of a tertiary-care children’s hospital using rituximab in the treatment of pediatric antineutrophil cytoplasmic…
Abstract Number: 303 • 2012 ACR/ARHP Annual Meeting
Ancestral Group Differences in Pediatric SLE Early Disease Severity: An Analysis of the Carranet Registry
Jennifer M.P. Woo¹, Alice DC Hoftman¹, Emily von Scheven², Deborah K. McCurdy³, Ornella J. Rullo¹ and CARRA Registry Investigators⁴, ¹Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ²Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴Durham, NC
Background/Purpose: Ancestral background may contribute to increased disease morbidity in patients with pediatric lupus systemic erythematosus (pSLE) of non-European descent; however, there exists a paucity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].